504|Walmir Coutinho
3.
Astrup A, Carraro R, Finer N, Harper A, Kunesova M and Lean M E J. (2012) Safety,
tolerability and sustained weight loss over 2 years with the once-‐daily human GLP-‐
1 analog, liraglutide. Internat J Obesity 36, 843–854.
4.
Barrera Cruz A, Rodríguez González A y Molina Ayala M A (2013) Escenario actual
de la obesidad en México. Rev Med Inst Mex Seguro Soc 51 (3), 292-‐299.
5.
Botella-‐Carretero J I, y cols. (2007) La deficiencia de vitamina D está asociada al
síndrome metabólico en la obesidad mórbida. Clinical Nutr 26 (5), 573-‐580.
6.
Campfield L A, Smith F J, Guisez Y, Devos R and Burn P. (1995) Recombinant
mouse Ob protein: evidence for a peripheral signal linking adiposity and central
neural networks. Science 269: 546-‐549.
7.
Considine R, Sinha M, Heimann L y cols. (1996) Serum Immunoreactive-‐Leptin
concentrations in normal weight and obese humans . New Engl J Med 334: 242-‐
245.
8.
Cuevas A y Reyes M S. (2005) Lo último en diagnóstico y tratamiento de la
obesidad. ¿Hay lugar aún para la terapia conservadora? Rev méd Chile. 133:713-‐
722.
9.
Fidler M C et al. (2011) A one-‐year randomized tria of lorcaserin for weight loss in
obese and overweight adults. : the Blossom Trial (For the Blossom clinical trial
Group). J Clin Endocrinol Metab 96:3067-‐3077.
10.
Galhardi CM, Diniz YS, Rodrigues HG, Faine LA, Burneiko RC, Ribas BO and Novelli
ELB (2005) Beneficial effects of dietary copper supplementation on serum lipids
and antioxidant defences in rats. Annals of Nutrition and Metabolism ISSN: 0250-‐
6807-‐2005.
11.
Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA et al. (2012)
Two-‐year sustained weight loss and metabolic benefits with controlled-‐release
phentermine/topiramate in obese and overweight adults (Sequel): a randomized ,
placebo-‐controlled, phase III extension study. Am J Clin Nutr 95: 297-‐308.
12.
Gilbert JA, Gasteyger C, Raben A, Meier DH, Astrup A, Sjödin A. (2012) The effect of
tesofensine on appetite sensations. Obesity (Silver Spring). 20 (3): 553-‐561.
13.
Gomis Barbará R (2004) Tratamiento farmacológico de la obesidad. Rev Med Univ
Navarra 48, 63-‐65.
14.
Grün F and Blumberg B. (2009) Endocrine disrupters as obesogens. Mol Cell
Endocrinol. 304, 19–29.
15.
Latili G, Gallo F and Lugheti L. (2010) Toxic environment and obesity pandemia: is
there a relationship? Ital J Pediatr. 36, 8.
16.
Martin Galicia I y Simal Antón A (2002) Tratamiento farmacológico de la obesidad.
Inf Ter Sist Nac Salud, 26: 117-‐127.
17.
Massachusetts Medical Society Committee on Nutrition. Obesity treatment using
drug therapy. White Paper April 17, 1996.
